Skip to search formSkip to main contentSkip to account menu

refractory chronic lymphocytic leukemia

Known as: Refractory CLL, chronic lymphocytic leukemia, refractory, Refractory Chronic Lymphoid Leukemia 
Chronic lymphocytic leukemia that is resistant to treatment.
National Institutes of Health

Related topics

Related topics

26 relations
Atypical lymphocyteB lymphoblastB-LymphocytesBCL3 gene

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Purpose: The oral BCL-2 inhibitor venetoclax is an effective therapy for patients with relapsed/refractory (R/R) chronic… 
Review
2018
Review
2018
BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.
Highly Cited
2018
Highly Cited
2018
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following… 
Highly Cited
2015
Highly Cited
2015
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimens
Ibrutinib is active in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). In patients treated with… 
Highly Cited
2014
Highly Cited
2014
Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.
GAUGUIN evaluated the safety and efficacy of obinutuzumab (GA101) monotherapy in patients with relapsed/refractory chronic… 
Highly Cited
2008
Highly Cited
2008
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
PURPOSE Richter's syndrome (RS) and fludarabine-refractory chronic lymphocytic leukemia (CLL) are associated with poor clinical… 
Highly Cited
2007
Highly Cited
2007
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
PURPOSE Expression of Bcl-2 protein is associated with chemotherapy resistance and decreased survival in chronic lymphocytic… 
Highly Cited
2005
Highly Cited
2005
Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.
PURPOSE Patients with chemotherapy-refractory chronic lymphocytic leukemia (CLL) have a short life expectancy. The aim of this… 
Highly Cited
2002
Highly Cited
2002
Frequency and type of serious infections in fludarabine‐refractory B‐cell chronic lymphocytic leukemia and small lymphocytic lymphoma
Treatments for fludarabine‐refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) are limited. Most new… 
Highly Cited
1991
Highly Cited
1991
2-Chlorodeoxyadenosine Treatment of Refractory Chronic Lymphocytic Leukemia.
Ninety patients with advanced refractory chronic lymphocytic leukemia (CLL) were treated with 2-chlorodeoxyadenosine (2-CdA… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)